

## Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Ranzenigo M, Gianotti N, Galli L, et al. *Drug Des Devel Ther.* 2022;16:1975–1982.

Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on INSTIs in 69 (65%)” should read “the ongoing regimen was based on NNRTIs in 32 (30.2%) and on INSTIs in 74 (69.8%)”.

Page 1977, Results, last paragraph, line one, the text “a longer exposure” should read “a shorter exposure”.

Page 1980, first paragraph, lines one and two, the text “(a longer history of infection and a previous diagnosis of AIDS)” should read “(a previous diagnosis of AIDS)”.

Page 1980, Table 2, last row, the category INSTI-based vs NNRTI-based for the BL ART (type of non-PI regimen) characteristic is incorrect and should read “NNRTI-based vs INSTI-based”. The correct Table 2 is shown below.

**Table 2** Factors Associated with the Switch to D/C/F/TAF

Characteristics	Category	Adjusted Hazard Ratio (95%CI)	p-value
Years of HIV	Per 1-year longer	0.947 (0.907-0.989)	0.014
Previous diagnosis of AIDS	Yes vs. No	3.260 (1.399-7.593)	0.006
Calendar year of BL ART	Per 1-more recent year	2.250 (1.609-3.148)	<.0001
BL triglycerides	Per 1-mg/dL higher	1.005 (1.003-1.008)	<0.0001
BL alanine transaminase	Per 1-U/L higher	1.008 (1.003-1.012)	0.003
BL ART (type of non-PI regimen)	NNRTI-based vs INSTI-based	0.307 (0.116-0.813)	0.017

**Notes:** Adjusted for age, BMI, previous diagnosis of AIDS, nadir CD4+, HBV, years of HIV, calendar year of non-PI regimen start, type of nonprotease inhibitor regimen, BL CD4+, gender, HIV risk factor; HCV, previous diagnosis of diabetes, previous diagnosis of cancer; previous diagnosis of hypertension, previous or current use of statin, BL HIV-RNA, duration of HIV-RNA <50 copies/mL, BL CD4+, BL CD8+, BL CD4+/CD8+ ratio, BL hemoglobin, BL platelets, BL estimated glomerular filtrate rate, BL fasting glucose, BL triglycerides, BL total cholesterol, BL Fibrosis-4 index, BL alanine transaminase, BL aspartate transaminase, BL total bilirubin, BL alkaline phosphatase.

**Abbreviations:** D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; AIDS, acquired immune deficiency syndrome; BL, baseline; ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.

The authors apologise for the errors and advise they do not affect the results of the paper.

Drug Design, Development and Therapy

Dovepress

## Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S394059>